Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.80 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.77 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.77 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.73 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | CDK8 | P49336 | 7/20 | 0.70 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.70 |
| ▸ | RET | P07949 | 4/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.66 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.66 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.66 |
| ▸ | MARK3 | P27448 | 1/20 | 0.66 |
| ▸ | FRK | P42685 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 1/20 | 0.66 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.66 |
| ▸ | STK3 | Q13188 | 1/20 | 0.66 |
| ▸ | PAK4 | O96013 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192079 | 0.93 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL3184766 | 0.92 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL2082021 | 0.92 | MAPK14 (0.86) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL5060097 | 0.91 | MAPK14 (0.85) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL2083690 | 0.90 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL13296444 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL3294729 | 0.89 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL2083216 | 0.89 | MAPK14 (0.86) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL3193403 | 0.89 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL2082028 | 0.88 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MAPK14 128/4885MAPK13 162/4885MAPK12 160/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MAPK14 100/4885MAPK13 118/4885MAPK12 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.